ECO 2026: gut hormone signals differ in T1D with obesity - Pharmaceutical Technology

At ECO 2026, researchers presented a study assessing fasting PYY, ghrelin and GIP levels in T1D patients, with or without obesity. While exploratory, the study adds to a growing body of evidence that obesity in T1D may not simply mirror obesity in type 2 diabetes (T2D) or the general population. Credit: ANDREI ASKIRKA via Shutterstock.com. At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY (PYY), ghrelin and glucose-dependent insulinotropic polypeptide (GIP) levels in people living with type 1 diabetes (T1D), with or without obesity. While exploratory, the study adds…

Source: Pharmaceutical Technology